Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Antimicrobial Stewardship (AMS) Interventions and Outcomes in Clinical Outcomes, Optimal Use and Resource UtilizatioRelease Date:Research Inflammation & Immunology China Optimizing Disease Management to Improve Alopecia Areata Quality of CareRelease Date:Quality Improvement Inflammation & Immunology China Research on Exploring Disease Assessment and Prioritizing Systematic Treatment for VitiligoRelease Date:Research Inflammation & Immunology China Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)Release Date:Partner: American Society for Clinical Pathology (ASCP)Quality Improvement Oncology USA Personalized monitoring&treatment for HR+, HER2- mBC patients treated w CDK4/6i: incorporating Patient complexity risk factorsRelease Date:Quality Improvement, Research Oncology Italy Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Administration of brentuximab vedotin alone or in combination with other approved agents in pre and/or peri CAR-TRelease Date:Research Oncology USA Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) TherapyRelease Date:Education Oncology Canada Title Grant Type Focus Area Country Application Due Date Education for Improving Appropriate Diagnosis and Treatment for Venous ThromboembolismRelease Date:Education Internal Medicine Japan Education and Support for Patients with Locally-Advanced or Metastatic Bladder CancerRelease Date:Partner: Merck KGaA, Darmstadt, Germany and EMD SeronoEducation Oncology USA Pre-clinical & Translational Research in Multiple MyelomaRelease Date:Research Oncology Canada, USA Management of Patients with BRAF-mutant metastatic colorectal cancerRelease Date:Education Oncology Canada, USA Promotion of Smoking Cessation Treatment in General PracticeRelease Date:Education Internal Medicine Japan Quality Improvement Grants to Support the Delivery of Gene Therapies to Patients with Rare DiseaseRelease Date:Quality Improvement Rare Disease All 2021 Growth Hormone Research (All countries except for the United States)Release Date:Research Rare Disease All Closing Knowledge Gaps in Osteoarthritis and Osteoarthritis PainEducation Internal Medicine All NSCLC Therapy Management for Optimal OutcomesRelease Date:Quality Improvement Oncology Andorra, Austria, Belgium, Canada, Denmark, France, Germany, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Spain, Sweden, Switzerland, USA, United Kingdom Clinical Research Capability DevelopmentRelease Date:Education Internal Medicine China Educational Program to Increase Awareness and Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Release Date:Education Rare Disease China Improve the care of patients living with metastatic breast cancerQuality Improvement Oncology Canada